Cases in CLL Slides: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy

Download this slideset for expert perspectives on third-line treatment considerations for patients with CLL requiring new treatment following BTK inhibitor– and venetoclax-based therapy.
Jeremy S. Abramson, MD, MMSc
Format: Microsoft PowerPoint (.ppt)
File Size: 2.97 MB
Released: October 14, 2020

Acknowledgements

Provided by University of South Florida (USF) Health in partnership with Clinical Care Options, LLC

USF Health
Office of Continuing Professional Development (OCPD)
124 S. Franklin Street
Tampa, FL 33602

(800) 852-5362
(813) 224-7860
(813) 224-7864 (Fax)
cpdsupport@usf.edu
https://health.usf.edu/cpd

Produced in collaboration with
CLL Society Logo
Educational grant provided by:
AbbVie Inc.
AstraZeneca
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

Preview expert ITP abstract selections from ASH 2020 as part of conference coverage from Clinical Care Options (CCO)

David J. Kuter, MD, DPhil Released: November 24, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue